Scleroderma is a connective tissue disease involving primarily the skin and subcutaneous tissue but may involve other organ systems such as the lungs, gastrointestinal tract, and heart. The most striking pathologic feature is the deposition of excess collagen in the affected tissues leading to fibrosis.
During the process of reviewing articles for this summary, it was interesting to observe that there is no uniform nomenclature. It appears that the word scleroderma is used to denote the entire group of conditions. The term sclerosis is used primarily to refer to the systemic variety. Of the two major types of scleroderma, localized and generalized, the localized variety is more common in children and is confined to skin and subcutaneous tissue unlike the systemic variety [1] . Most classification systems subdivide this localized scleroderma into superficial lesions (morphea) and deep lesions (linear scleroderma). Morphea is further subdivided into localized and generalized. A subset of linear scleroderma is en coup de sabre of the face and scalp. In an alternate system proposed by the Mayo Clinic group, the term morphea is applied to this entire group of conditions [2] . In a conference on juvenile scleroderma held at Padua, Italy, in June 2001, preliminary criteria for the classification of juvenile localized scleroderma was proposed with seven subtypes. Efforts are underway to test these criteria before recommendations can be made for universal use.
The generalized variety, called systemic sclerosis (SSc), is less common in children. Preliminary criteria for the classification of SSc proposed by the American College of Rheumatology were meant to minimize false-positive diagnoses. Three developments have made it possible and necessary to diagnose SSc in the preclinical stage before skin lesions develop and criteria are fulfilled. They are (1) a better understanding of the Raynaud phenomenon, (2) the role of nailfold microscopy in the diagnosis and prognosis, and (3) the enlarging profile of autoimmune serology [3••]. Because signs and symptoms of organ involvement evolve over years and decades, it is useful to diagnose some of these patients before classic skin changes occur. This is reflected in the current classification of the subsets of SSc (Table 1) with the inclusion of the autoimmune Raynaud phenomenon.
To identify patients with vascular abnormalities and serologic changes typical of SSc but who do not fulfill criteria for diffuse cutaneous systemic sclerosis (dcSSc) or limited cutaneous systemic sclerosis (lcSSc) ( (Table 2 ). According to this recommendation, patients who exhibit the Raynaud phenomenon and either nailfold capillary abnormalities or an antibody characteristic of dcSSc or lcSSc are classified as having the limited form of SSc (lSSc). In my view, this category is particularly useful for children, and a prospective study to test this idea would be helpful.
There were several papers written in 2001 on the clinical manifestations of SSc in the adult population. One important paper on the clinical aspects of SSc in children reported new onset of SSc 9 months after cessation of chemotherapy for thyroid carcinoma in a 13-year-old girl [5] . In adults, there is a 1.5-fold increase in the incidence of cancer in patients with scleroderma [6] . Such an association is distinctly rare in children.
There are several isolated reports of familial occurrence of SSc. In a prospective survey of three large cohorts of patients with SSc in the United States, Arnett et al. [7••] found that SSc occurred in 1.5 to 1.7% of first-degree relatives compared with the estimated prevalence of 0.26%. RR for first-degree relatives was high; however, absolute risk was low (<1%).
High-resolution CT has become an important modality to investigate pulmonary disease in general and SSc in particular. Using this technique, Andonopoulos et al. [8•] found bronchiectasis in 13 of 22 patients (60%) with SSc. Interestingly, these changes were found in both dcSSc and lcSSc and did not correlate with the diffusing capacity for carbon monoxide (DLCO) or the presence of a ground-glass appearance in plain films. This association had not been recognized in the past.
In another study from Korea, Kim et al. [9•] reported 23 patients with lcSSc and 17 with dcSSc who had clinically defined interstitial lung disease. Serial high-resolution CT studies were done with a mean follow-up of 39 months. Most common abnormalities seen in highresolution CT were ground-glass opacity, linear irregular opacity, small nodules, consolidation, honeycombing, and bilateral pleural thickening. In the 17 patients for whom data on pulmonary function tests were available, there was a correlation between ground-glass appearance in high-resolution CT and DLCO.
Renal disease with hypertension and rapid progression to renal failure are known complications of dcSSc. Pulmo- nary hypertension (PH) without pulmonary fibrosis is a known complication of lcSSc. It is rare to see a combination of these two potentially fatal problems in the same patient. The Pittsburgh group found such a combination in 11 of a cohort of 2459 patients (0.45%). Seven had lcSSc and four had dcSSc. Renal crisis occurred earlier in all but one. PH became evident after a mean period of 4.3 years. Interestingly, none had anticentromere antibody or antitopoisomerase antibody. Therefore, it is important to screen patients with scleroderma renal crisis who do not have either of these antibodies for other antibodies: anti-Th/TO, POL III, and U 3 RNP. Those who have one of these antibodies have an increased risk of developing PH later [10••].
Edema is a known feature of early lesions of scleroderma. This is generally described as nonpitting. Englert and Low [11] suggest that pitting edema may be seen in early diffuse SSc. They also describe a quantitative method to follow this finding by the Skin Pitting Oedema Time test (SPOT test) by measuring the time it takes for the depressed skin to recover.
Gastric antral vascular ectasia or "watermelon stomach" of scleroderma was initially described in 1984 by Jabbari et al. [12] . Pathologically, this lesion is characterized by chronic inflammatory infiltrate, capillary dilation, and fibromuscular dysplasia of the lamina propria and muscular layers. Patients with this lesion often develop severe recurrent anemia requiring transfusion. In one report of this condition in a 72-year-old patient with dcSSc and recurrent severe anemia, Raynaud phenomenon, and pulmonary fibrosis, treatment with intravenous cyclophosphamide and methylprednisolone for the primary disease resulted in improvement of the gastric ectasia [13].
It is not surprising to find that such vascular ectasia can affect the lower end of the gut also (watermelon rectum).
Singh et al.
[14•] reported a 39-year-old woman with severe, rapidly progressive SSc who developed iron deficiency anemia and guaiac-positive stool. On endoscopy, this patient was shown to have watermelon stomach. In addition, the rectum also showed vascular stripes and on biopsy showed dilated capillaries and focal hyalinization of the lamina propria.
In an excellent review of the classification of abnormali Psychological problems and reactive depression are common in patients with chronic illnesses. This is a particular problem for those with cosmetic defects. Therefore, it is no surprise that patients with SSc have variety of psychological problems. Angelopolous et al.
[17] studied 30 women with different types of SSc and 30 normal controls. Various measurement tools were used to measure hostility, anxiety, depression, and delusions. Most patients with SSc showed anxiety and depression. Somatization, deep feelings of generalized hostility and guilt, and interpersonal sensitivity were also seen in these patients. There were weaknesses in this study, including the lack of a control group of patients with other skin conditions and the lack of formal psychiatric testing.
All these papers reported on adults. There were two reviews devoted to scleroderma in children. (Table 3) . These studies are of great importance because the recognition of early steps in the pathogenesis may lead to the development of more rational treatment of this difficult to treat condition.
The early infiltrates of mononuclear cells release several cytokines and chemokines that in turn have effects on both endothelial cells and fibroblasts. In addition to cytokines, several growth factors have also been noted in scleroderma skin. These include transforming growth factor-␤ (TGF-␤), platelet-derived growth factor, connective tissue growth factor (CTGF), and endothelin-1. There has been particular interest recently in the role of TGF-␤ because it has important actions on fibroblasts and endothelial cells. TGF-␤ has been shown in vitro to stimulate the synthesis of extracellular matrix components including collagen types I and III [21] . TGF-␤ also promotes fibrosis indirectly by inhibiting collagenase activity [22] . Several recent studies emphasize the role of metalloproteinases (which are collagenases) and their inhibitors (tissue inhibitors of matrix metalloproteinase [TIMP]) on fibrosis.
Ihn et al.
[23••] studied fibroblasts from the skin of patients with diffused SSc and from healthy controls. Production of TGF-␤1 was similar in patients and controls, but fibroblasts from the skin of patients with SSc expressed increased levels of TGF-␤1 and TGF-␤2 receptor proteins compared with controls. Also, on treatment with anti-TGF-␤ antibody, normal fibroblasts showed little reduction in human ␣ 2 -I collagen messenger RNA expression, whereas SSc fibroblasts showed marked dose-dependent reduction in expression of human ␣ 2 -I collagen messenger RNA. Similar effects were produced when patients with SSc were exposed to antisense nucleotide for TGF-␤1. In other words, blockade of TGF-␤1 signaling inhibits upregulation of collagen synthesis in SSc fibroblasts.
Another growth factor, CTGF, is also getting increased attention. Earlier studies showed that CTGF is upregulated in fibroblasts cultured from patients with scleroderma [24] . (Another name for CTGF is ccn2.) Stratton et al. [25] showed that CTGF levels are greatly elevated in the dermis of patients with scleroderma compared with controls and that infusion with iloprost produced a decrease in the CTGF levels. Although TGF-␤1 is known to initiate fibrosis, it appears that CTGF plays a greater role in maintaining and promoting fibrosis. TGF-␤1 appears to control CTGF expression, and this appears to be owing to a special binding element in the CTGF promotor region (originally known as TGF-␤2 responsive enhancer). It also appears that there is an inherent increase in basal CTGF promotor activity in scleroderma fibroblasts [26] .
Systemic sclerosis is characterized by increased production of connective tissue, notably collagen. The observed excess of collagen in the extracellular matrix maybe owing to increased production or decreased degradation of the matrix components or both. The decreased degradation of matrix may again be owing to (1) reduced serum levels of matrix metalloproteinase (MMP) or (2) increased levels of TIMPs. Fibroblasts produce MMP, which digests matrix components. Of these, MMP-1 (interstitial collagen I) is the one most studied. Fibroblasts also produce inhibitors of MMP known as TIMPs, and there are four such TIMPs. Several studies looked at the role of MMP-1 and TIMP in patients with scleroderma.
Young-Min et al.
[27•] showed that TIMP-1 levels were significantly increased in the serum from patients with both dcSSc and lcSSc compared with controls. Elevated TIMP-1 did not correlate with the presence of other autoantibodies or with organ damage. TIMP-2 and MMP-1 serum levels, however, did not show any such abnormalities. Interestingly, the TIMP-1 level was not increased in patients with Raynaud phenomenon. These findings suggest that the balance between MMP-1 and TIMP-1 may be important in excess accumulation of collagen in SSc.
Several findings suggest that cellular immunity plays a major role in the initiation of systemic scleroderma. These include (1) the presence of mononuclear cell infiltrate in the early lesions, (2) altered function of Thelper and natural killer cells, and (3) the release of various cytokines [28] . Cytokines and growth factors involved in the regulation of fibroblast functions are shown in Table 3 . In addition, chemokines produced by white cells may play a role in the recruitment of specific types of leukocytes to the involved skin and tissues. Of these, MCP-1, which attracts monocytes, and MIP-1, which attracts monocytes and T-helper cells, are known to play a part in SSc. The serum levels of these proteins are known to be elevated in pulmonary fibrosis [29] . Galindo et al. [30•] showed that nonstimulated fibroblasts from normal skin and scleroderma skin express both MCP-1 and IL-8 constitutively. In systemic scleroderma skin, there was constitutive overexpression of MCP-1 messenger RNA, and this was detected in the fibroblasts, keratinocytes, and mononuclear cells. MCP-1 production was also shown to be associated with increased chemotactic activity of monocytes.
Distler et al. [31] confirmed these findings. Using in situ hybridization technology, they showed that MCP-1 was expressed by fibroblasts, keratinocytes, and mononuclear cells in both involved and uninvolved skin. Stimulation with platelet-derived growth factor resulted in increased MCP-1 messenger RNA and MCP-1. Treatment of the skin with antibodies to MCP-1 resulted in reduced chemotactic activity. These data indicate that MCP-1 might be an important agent in the initiation of inflammatory infiltrates in the skin of patients with SSc.
Mast cells are known to play a part in tissue fibrosis. However, the exact mechanism by which fibrosis is produced by mast cells is not known. Recent studies indicate that mast cells produce several cytokines and growth factors that are known to be involved in fibrosis. Yamamoto et al. [32] showed that stem cell factor, a mast cell growth factor, upregulates MCP-1 gene expression in the normal mast cell line and human normal skin fibroblasts. This effect is time dependent. They also showed increase concentration of stem cell factor in the culture supernates of scleroderma fibroblasts. The hypothesis is that mast cell stem cell factor may upregulate MCP-1 expression and synthesis in fibroblasts. This in turn may enhance ␣-I collagen messenger RNA expression leading to increased collagen production and fibrosis.
The idea of microchimerism as a possible cause of scleroderma comes from studying chronic graft versus host disease. This is a chimeric disorder in which T cells or natural killer cells of the donor tissue act against the HLA of the recipient [33••] . Microchimerism is defined by the presence within an individual of a very low level of cells derived from different individuals. Common situations in which microchimerism is seen are (1) women who had previous pregnancies, (2) individuals who have had blood transfusions, and (3) a child with cells either from the mother or a twin. It is known that maternal cells can persist in an immunocompetent offspring even in adult life. Fetus-derived hemopoietic cells have been shown in maternal circulation for as long as 27 years postpartum. Fetal DNA has been shown for even longer periods [34, 35] . Although microchimerism can be seen in normal subjects and in other diseases, it has been pro-posed as a possible factor in the production of autoimmune diseases [36] .
In a recent study of tissue specimens obtained at autopsy of women with SSc, male cells were observed in tissue from at least one site in every woman with SSc and none in tissues from women without SSc [37•]. Although this confirms the earlier finding of the presence of fetal cells in women several decades after childbirth, more definitive studies are needed to show whether these cells are responsible for the disease or whether these cells migrated and expanded at tissue sites secondary to immunostimulation.
Another study of the role of 5-lipoxygenase in the skin of fibroblasts with SSc is intriguing because it opens up another area of investigation both to explain the early inflammation in scleroderma and to target therapy [38• ].
Finally, the presence of excess collagen in scleroderma can be explained based on either increased production or decreased destruction. Santiago et al. [39•] showed that there is a defect in the regulation of apoptosis of fibroblasts. This is an interesting finding because this may open up new avenues for treatment.
Treatment
In a superb review of the treatment of scleroderma, Denton and Black [20••] point out correctly that no agent has yet been shown to be superior to placebo as a diseasemodifying agent. However, with increasing understanding of the pathogenesis of this disease, chances for more rational therapy are increasing. Based on the current concept of pathogenesis, treatment approaches are aimed at (1) immunomodulation, (2) changing vascular tone, and (3) controlling fibrosis (Fig. 1) .
Among the immunomodulatory drugs, current interest revolves around methotrexate. Pope et al. [40• ] studied 71 patients with early SSc within 3 years after diagnosis in a multicenter, randomized, placebo-controlled, double-blind trial. Treatment with methotrexate at doses of 15 mg per week was administered for 12 months. Primary outcome measures were skin score and physician global assessment. There was a trend in favor of methotrexate compared with placebo. However, the differences were small.
In an earlier study, Uziel et al. [41] summarized their experience with the use of methotrexate in ten pediatric patients with localized scleroderma. Methotrexate (0.3 to 0.6 mg/kg per week) was used in addition to steroids during the initial 3 months. It appears that nine of these patients responded and tolerated the treatment. However, a placebo-controlled study is essential before this can be recommended as a routine.
Cytoxan (cyclophosphamide) has been shown to be effective in the treatment of interstitial lung disease of SSc when used during the exudative phase [42] . European experience with human stem cell transplant using Cytoxan and granulocyte-colony stimulating factor treatment with T-cell depletion showed frequent improvement in skin score but increased mortality [43] . There was a brief report on the use of high-dose Cytoxan (50 mg/kg per day for 6 days) and antithymocyte globulin (30 mg/kg per day for 3 days) followed by infusion with CD34-enriched autologous stem cells in a patient with chronic graft versus host disease. This patient showed marked improvement in skin thickness, lung disease, and quality of life [44] .
There are several pharmacologic actions of Dpenicillamine on collagen metabolism and immunoglobulins to suggest that it may be effective in the treatment of scleroderma syndromes. Although earlier retrospective studies suggested that it may be useful, a recent multicenter randomized trial in adults with SSc using highand low-dose therapy did not establish the effectiveness of D-penicillamine. Interestingly, low-dose therapy was found to be probably more effective than high-dose therapy. Two articles give different and opposing points of view on this specific study. Furst and Clements [45••] interpreted the study to show that D-penicillamine is ineffective in the treatment of SSc. Their argument is based on the fact that this was a well-controlled, doubleblind study using strict outcome measures. However,
Medsger et al. [46••] , in their contrasting point of view, argue that the study was defective because there was no placebo group. They used historical data from studies in which a placebo group was used and showed that there were more responders in the scleroderma group compared with the historic placebo group. They also suggested that the current study could be interpreted to show that a low dose is also effective.
Increased vascular tone and endothelial damage of the vessel wall are important pathologic features of SSc. Traditionally, calcium channel blockers have been used for the treatment of the Raynaud phenomenon. Angiotensin-converting enzyme inhibitors have been used with dramatic results in scleroderma renal crisis with hypertension. Newer agents used to treat vascular problems associated with scleroderma include Losartan, which is an antagonist of angiotensin receptor. In a meta-analysis of the use of calcium channel blockers used to treat the Raynaud phenomenon, Thompson et al. [47••] concluded that improvement in both the frequency and severity of ischemic attacks in the Raynaud phenomenon seen in association with scleroderma is only moderate and that more larger randomized trials are needed.
Other classes of agents that may be of use in the treatment of the Raynaud phenomenon include prostacyclin analogs and antioxidants. Prostaglandin I 2 (prostacyclin) has been shown to reduce the frequency and severity of vasospasm in many open trials. However, this requires continuous infusion because this compound has a very short half-life. Therefore, chemically stable analogs of prostaglandin I 2 have been synthesized with vasodilatory and antiplatelet aggregation activities. Iloprost has been the most studied of these analogs. Another stable derivative of prostaglandin E 1 , namely prostaglandin E 1 -␣cyclodextrin was used in an open study of 36 patients with SSc [48] . The Raynaud phenomenon improved in 87% of the patients. There was also an associated reduction in the plasma levels of c intercellular adhesion molecule-1 and tissue plasminogen activator, suggesting improvement in endothelial function.
There is increased recognition of the role of growth factors in the cause of fibrosis. Therefore, it is interesting to note that after iloprost infusion, there is a marked reduction in the production of CTGF in the dermis of patients with scleroderma [25] . Thus, iloprost may have an antifibrotic effect in addition to its effects on the blood vessels.
Several recent reports suggest that free radical activity may be important in the cause of endothelial damage in SSc. Therefore, it is reasonable to speculate that antioxidants may be of use in reducing early vascular damage.
In a multicenter open trial, Sambo et al.
[49•] showed that intravenous infusion with N-acetyl-cysteine resulted in significant reduction in the frequency and severity of Raynaud phenomenon attacks after treatment. The treatment was well tolerated. This approach may also be of use in children.
Pulmonary hypertension is secondary to lung disease in dcSSc, whereas isolated PH without lung disease is seen more often in lcSSc. PH is a major cause of death in SSc with a median survival of 2.5 years from the time of diagnosis. Based on experience in primary PH, one patient with severe PH associated with lcSSc underwent atrial septostomy with substantial clinical improvement [50] . This treatment cannot be undertaken lightly because this is only a palliative procedure and overcorrection and inadequate correction have serious consequences.
Measurements in scleroderma
There are several problems in conducting clinical and therapeutic trials in scleroderma. The reasons are (1) the small number of patients in any one center, (2) the heterogeneity of the diseases, (3) the lack of methodologies to quantitate and document disease activity, chronic damage, and improvement or worsening of the disease [20••]. Several studies are in progress to correct these deficiencies. The European Scleroderma Study Group started a multicenter effort in 1995 to develop a valid set of criteria to assess disease activity. All 19 participating centers were required to follow the same well-defined protocol. Despite clear guidelines on the definition of skin and organ involvement, there were considerable differences between centers in the use of diagnostic tests and therapeutic approaches. The authors concluded that there is a need to define precisely the clinical parameters, establish a consensus on the controversial aspects of the disease, and determine a set of simple and inexpensive tests that can be uniformly performed in all patients [51••] .
In a subsequent study, the European Scleroderma Study Group developed three different ten-point indices of disease activity. All were validated and receiver operating curves were constructed. These were used as preliminary disease activity criteria: one for SSc as a group, one for lcSSc, and one for dcSSc [52••] . These require further validation. No such tool exists for scleroderma in children. However, the European Pediatric Rheumatology Society is developing plans to study pediatric scleroderma.
Earlier studies have shown that the Disability Index of the Health Assessment Questionnaire can be used to measure disability in SSc and that the Health Assessment Questionnaire Disability Index correlated with severity of the disease [53] . In a recent study, Clements et al. [53] showed that a Disability Index of more than 1 predicted mortality and that it correlated with several other measures of disease activity [54] .
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